Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

Study Overview
=================
Brief Summary
-----------------
The investigators aim to learn more about symptoms suggestive of a neurodegenerative process.

Detailed Description
-----------------
The investigators will recruit participants with symptoms suggestive of a neurodegenerative and/or related disease. Participants could be evaluated on a yearly basis, undergoing a baseline visit and possible follow-up evaluations with an interval of one year. At each visit, participants could undergo any combination of the following based on their symptoms and complaints: a neurological assessment, a speech/language assessment, a neuropsychometric assessment, an MRI, an FDG PET/CT scan, a PiB PET/CT scan, a Tau PET/CT scan and/or a C-11 ER176 PET/CT scan. All participants will be asked to provide a blood sample to allow for future genetic studies.

Official Title
-----------------
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

Conditions
-----------------
PSP, CBD, PCA, LPA, Semantic Dementia, Semantic Aphasia, Behavioral Variant of Frontotemporal Dementia, FTD, PPA, Apraxia of Speech, MSA - Multiple System Atrophy, Parkinson Disease

Intervention / Treatment
-----------------
* Drug: C-11 PiB
* Drug: AV1451 Tau
* Drug: C-11 ER176


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All participants will be over the age of 21 Have symptoms suggestive of a neurodegenerative and/or related disorder Exclusion Criteria: Participants will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes Women that are pregnant or post-partum and breast-feeding will be excluded Participants will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, Hypogammaglobulinemia, Wiskott-Aldrich syndrome and Down's syndrome Participants will be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts) Participants will be excluded if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy)

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neurodegenerative symptoms<br> | Drug: C-11 PiB<br>* Completing PET scan looking for amyloid protein<br>Drug: AV1451 Tau<br>* Completing PET scan looking for tau protein<br>Drug: C-11 ER176<br>* Completing PET scan looking for neuroinflammation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Imaging analysis | Longitudinal images and correlates will be measured and tracked to determine direct correlations in the brain with disease progression on a yearly basis | 1 year |